JP2015517504A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517504A5
JP2015517504A5 JP2015511877A JP2015511877A JP2015517504A5 JP 2015517504 A5 JP2015517504 A5 JP 2015517504A5 JP 2015511877 A JP2015511877 A JP 2015511877A JP 2015511877 A JP2015511877 A JP 2015511877A JP 2015517504 A5 JP2015517504 A5 JP 2015517504A5
Authority
JP
Japan
Prior art keywords
chelate complex
seq
pharmaceutical composition
interferon
oligonucleotide consisting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/050379 external-priority patent/WO2013170386A1/en
Publication of JP2015517504A publication Critical patent/JP2015517504A/ja
Publication of JP2015517504A5 publication Critical patent/JP2015517504A5/ja
Pending legal-status Critical Current

Links

JP2015511877A 2012-05-18 2013-05-17 オリゴヌクレオチドキレート錯体−ポリペプチド組成物および方法 Pending JP2015517504A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US61/648,711 2012-05-18
US201261695035P 2012-08-30 2012-08-30
US61/695,035 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (2)

Publication Number Publication Date
JP2015517504A JP2015517504A (ja) 2015-06-22
JP2015517504A5 true JP2015517504A5 (enExample) 2016-07-07

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511877A Pending JP2015517504A (ja) 2012-05-18 2013-05-17 オリゴヌクレオチドキレート錯体−ポリペプチド組成物および方法

Country Status (34)

Country Link
US (1) US9492506B2 (enExample)
EP (1) EP2849798B1 (enExample)
JP (1) JP2015517504A (enExample)
KR (1) KR102068109B1 (enExample)
CN (1) CN104349793B (enExample)
AU (1) AU2013262416B2 (enExample)
BR (1) BR112014028654A2 (enExample)
CA (1) CA2873529C (enExample)
CL (1) CL2014003134A1 (enExample)
CO (1) CO7131387A2 (enExample)
CR (1) CR20140527A (enExample)
CY (1) CY1124345T1 (enExample)
DK (1) DK2849798T3 (enExample)
DO (1) DOP2014000264A (enExample)
EA (1) EA035967B1 (enExample)
EC (1) ECSP14027694A (enExample)
ES (1) ES2873844T3 (enExample)
HR (1) HRP20210840T1 (enExample)
HU (1) HUE054875T2 (enExample)
IL (1) IL235548B (enExample)
LT (1) LT2849798T (enExample)
MX (1) MX346239B (enExample)
MY (1) MY168778A (enExample)
NZ (1) NZ703095A (enExample)
PH (1) PH12014502551B1 (enExample)
PL (1) PL2849798T3 (enExample)
PT (1) PT2849798T (enExample)
RS (1) RS62030B1 (enExample)
SG (1) SG11201407599SA (enExample)
SI (1) SI2849798T1 (enExample)
SM (1) SMT202100319T1 (enExample)
TW (1) TWI635864B (enExample)
WO (1) WO2013170386A1 (enExample)
ZA (1) ZA201408674B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943591B2 (en) 2007-05-11 2011-05-17 Adynxx, Inc. Gene expression and pain
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112015003985A2 (pt) * 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d
JP2017521433A (ja) * 2014-07-10 2017-08-03 レプリコール インコーポレーティッド B型肝炎およびd型肝炎ウイルス感染の治療のための方法
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
AU2019376079A1 (en) * 2018-11-08 2021-05-27 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2024255846A1 (en) * 2023-06-16 2024-12-19 Ractigen Therapeutics Oligonucleotide formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルb型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CN1694959B (zh) * 2002-09-13 2013-09-18 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
EP1597278A4 (en) 2003-02-26 2006-03-22 Intermune Inc COMPOSITIONS OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON AND METHOD FOR THE APPLICATION THEREOF
US20060003942A1 (en) * 2003-10-27 2006-01-05 Roger Tung Combinations for HCV treatment
JP2008516996A (ja) * 2004-10-19 2008-05-22 レプリコール インコーポレーティッド 抗ウイルス性オリゴヌクレオチド
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
EP1942911A4 (en) * 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
WO2009076679A2 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
ES2618576T3 (es) * 2009-05-28 2017-06-21 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
EP2512491B1 (en) * 2009-10-16 2017-10-11 Glaxo Group Limited Hbv antisense inhibitors
HUE029521T2 (en) * 2010-08-20 2017-03-28 Replicor Inc Oligonucleotide chelate complexes
BR112015003985A2 (pt) 2012-08-30 2017-08-08 Replicor Inc métodos para tratamento de infecções de hepatite b e hepatite d

Similar Documents

Publication Publication Date Title
JP2015517504A5 (enExample)
JP2015528449A5 (enExample)
JP5578853B2 (ja) ウイルス感染の治療のための化合物、及び医薬組成物
HRP20201953T1 (hr) Postupci i farmaceutski pripravci za liječenje virusne infekcije hepatitisom b
JP2006516949A5 (enExample)
US6566344B1 (en) β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US9504705B2 (en) Hepatitis C viral infection treatment using a combination of compounds
JP2004513070A5 (enExample)
TWI620568B (zh) 用於治療b型肝炎及d型肝炎感染之方法
JP2013507439A5 (enExample)
JP2007269798A (ja) B型肝炎の治療のためのβ−L−2’−デオキシ−ヌクレオシド
JP2017521433A5 (enExample)
JP2015512860A5 (enExample)
JP2009504157A5 (enExample)
JP2013522302A5 (enExample)
JP2016531144A5 (enExample)
CA2498731A1 (en) .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
Brunetto et al. Interferon therapy of chronic hepatitis B
JP2004533401A5 (enExample)
HRP20231400T1 (hr) Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
TWI635864B (zh) 寡核苷酸螯合複合物-多肽組合物及方法
HRP20150430T1 (hr) Lijeäśenje same virusne infekcije hepatitisa b ili kombinirane s delta virusom hepatitisa te povezanih jetrenih bolesti
CN104968673A (zh) 融合多肽及使用方法
TW202146011A (zh) 治療b型肝炎病毒感染之組合療法
Buster et al. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos (t) ide analogues